What makes the matter more difficult is that science has not yet reached an effective treatment for the disease, despite the strenuous efforts in this field, so the recent announcement of approval US Food and Drug Administration About a new drug that would slow cognitive decline in the early stages of the disease, a revolution in the world of medicine.
What you should know about the new medicine
- The drug is named "Likembe" (This group)Also known as the Lucanimab (lecanemab).
- poses "Licanimab" Its active ingredient, and given to patients intravenously once every two weeks.
- Preliminary data from the Liquimbe trial, published in September, showed the drug slowed cognitive decline in Alzheimer’s patients by 27 percent over an 18-month period..
- The property is developed by my company "Esay" Japanese, f"Biogen" American.
How it works?
- The drug targets protein deposits "amyloid".
- plaques "amyloid" They form around the neurons of Alzheimer’s patients, and in the long term destroy them, causing memory loss.
Side effects
- The US Food and Drug Administration, revealed that there is "Side effects" Negativity appeared during the experiments.
- The administration warned of abnormalities associated with amyloid, which may lead to temporary swelling in areas of the brain, which usually goes away with time.
- The swelling may be accompanied by small spots of bleeding, in or on the surface of the brain.
- Some people may experience symptoms such as headache, confusion, dizziness, change in vision, nausea, and seizures.
- Intravenous reactions may also occur, with flu-like symptoms, nausea, vomiting, and changes in blood pressure.
Alzheimer’s patients and their doctors will have to decide whether these problems are worth enduring against the drug’s benefit, which could potentially amount to slowing the disease for months..
the price
- company "Esay" She explained that she priced her property at $26,500 a year.
- Analysts from "Wall Street" They had expected that the price of the property would be about $ 20,000 annually, as expected by the analyst at the company "William Blair"Miles Minter, at the end of last year, priced closer to $28,000.
Real estate leave controversy
- Recall that the US Food and Drug Administration, developed "Licanumab" On fast track approval, for people with early stages of a degenerative brain disease.
- The approval came a few days after the report for CongressIn it, he sharply criticized the administration for giving the green light to another drug to treat Alzheimer’s patients "Aduhelm" (Aduhelm).
- In turn, the administration said that "Lekembe and Adohelm represent an important advance in the ongoing battle to effectively treat Alzheimer’s disease".
“>
Prepare Alzheimer’s One of the diseases that greatly affects human life, and puts enormous psychological pressure on those around the patient, who watch him gradually “leave” and his personality features disappear little by little.
What makes the matter more difficult is that science has not yet reached an effective treatment for the disease, despite the strenuous efforts in this field, so the recent announcement of approval US Food and Drug Administration About a new drug that would slow cognitive decline in the early stages of the disease, a revolution in the world of medicine.
What you should know about the new medicine
- The property is namedLikembe“ (This group)Also known as the Lucanimab (lecanemab).
- Licanimab is its active ingredient, and it is given to patients intravenously once every two weeks.
- Preliminary data from the Liquimbe trial, published in September, showed the drug slowed cognitive decline in Alzheimer’s patients by 27 percent over an 18-month period..
- The property is developed by my company.Esay“Japanese,” andBiogenAmerican.
How it works?
- The drug targets protein deposits.amyloid“.
- Amyloid plaques form around the neurons of Alzheimer’s patients, destroying them in the long run, causing memory loss.
Side effects
- The US Food and Drug Administration revealed that there were negative “side effects” that appeared during the experiments.
- The administration warned of abnormalities associated with amyloid, which may lead to temporary swelling in areas of the brain, which usually goes away with time.
- The swelling may be accompanied by small spots of bleeding, in or on the surface of the brain.
- Some people may experience symptoms such as headache, confusion, dizziness, change in vision, nausea, and seizures.
- Intravenous reactions may also occur, with flu-like symptoms, nausea, vomiting, and changes in blood pressure.
Alzheimer’s patients and their doctors will have to decide whether these problems are worth enduring against the drug’s benefit, which could potentially amount to slowing the disease for months..
the price
- The company, Esay, said it priced its property at $26,500 a year.
- Analysts from “Wall Street” had expected that the price of the property would be about $ 20,000 annually, while the analyst at “William Blair” company, Miles Minter, expected at the end of last year, a price closer to $ 28,000.
Real estate leave controversy
- The US Food and Drug Administration has put licanumab on the fast track for approval for people with early stages of the disease, which causes deterioration of the brain.
- The approval came a few days after the report for CongressIn it, he sharply criticized the administration for giving the green light to another drug to treat Alzheimer’s patients, which is “Aduhelm” (Aduhelm).
- In turn, the administration said, “Lekembe and Adohelm represent important progress in the ongoing battle to effectively treat Alzheimer’s disease.”“.